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Back&round: Bayer originally produced aspirin, the first nonsteroidal anti-
inflammatory drug (NSAID), in 1899. Today, more than 80 billion aspirin tablets 
are taken each year in the United States. Along with the popularity of over-the-
counter NSAIDs, prescription NSAIDs have become the most widely prescribed 
drugs in the world. While the drugs relieve minor pain, decrease fever, and reduce 
inflammation, NSAIDs can have serious side effects when used for a long period 
of time. The more dangerous side effects include GI ulcers, bleeding, and renal 
failure. Since 25% of people who regularly use NSAIDs experience side effects, a 
better option for long-term treatment is needed. 1 
The negative side effects ofNSAIDs are due to the inhibition of the constitutive 
enzyme prostaglandin H2 synthase-l (COX-I). This enzyme is responsible for the 
production of prostacyclin, which protects the gastric mucosa, and prostaglandin 
E2, which is needed by the kidneys. The desired effects ofNSAIDs-pain and 
fever relief-are brought about by the inhibition ofCOX-2, an isoenzyn1e of 
COX-I. COX-2 is induced after an injury or other inflammatory stimulus. It is 
responsible for the production of the prostaglandins that lead to inflammation. 
The problem with traditional NSAIDs is that these drugs inhibit the "good" COX-
1 enzyme more efficiently than they inhibit the "bad" COX-2. In fact, aspirin is 
10 to 100 times more effective against COX-I. 2 
This problem has now been solved by the introduction of selective COX-2 
inhibitors. One of the first COX-2 inhibitors to be developed is 
0-(acetoxyphenyl)hept-2-ynyl sulfide (APHS). This drug is similar to aspirin in 
that it inactivates cyclooxygenase by acetylation, but it is 60 times as reactive 
against COX-2 and 100 times as selective as aspirin.3 The first COX-2 inhibitor to 
be made available by prescription is celecoxib. The FDA approved celecoxib for 
the treatment of adult rheumatoid arthritis and osteoarthritis in December of 1998, 
and it is now sold under the trade name Celebrex. Another COX-2 inhibitor 
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approved for human use is rofecoxib-referred to commercially as Vioxx. It 
produces similar results as the celecoxib, and it is particularly beneficial for people 
who are sensitive to sulfonamide drugs. All of these drugs demonstrate the same 
analgesic and anti-inflammatory benefits ofNSAIDs without the side effects of 
extensive COX-1 inhibition, and research indicates that COX-2 inhibitors may 
have even more uses. One probable use for COX-2 inhibitors is in the treatment 
of colorectal cancer-people with long-term NSAID use show a 40-50% reduction 
in colon cancer risk.4 
Celecoxib Rofecoxib 
Introduction: Cancer of the colon and rectum is the third most diagnosed form of 
cancer in United States. Approximately 133,500 new cases of colorectal cancer 
were diagnosed in 1996, and in the same year about 54,900 people died as a direct 
result of this disease. Thanks to advances in treatment and a greater understanding 
of risk factors, the mortality rate for colorectal cancer is decreasing. Some 
important risk factors for the disease are age, a family history of colorectal cancer, 
sex, and inflammatory bowel disease, but approximately 75% of colon cancer 
patients have no known predisposing factors for colorectal cancer. Because these 
patients do not exhibit the established risk factors for colorectal cancer, they are 
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often not screened for the disease. In fact, the 1992 National Health Interview 
Survey found that only 17.3% of the American population above the age of 50 had 
been screened that year by fecal occult blood testing, a comn10n screening 
method. 5 
Increased screening of the general population is needed because the chances of 
survival of colorectal cancer are greatly increased by early detection. When the 
disease is detected in its early stages, the available treatments are more effective. 
If the cancer involves only the bowel wall, the five-year survival rate is about 
90%, but this rate falls to less than 10% if the cancer has metastasized. According 
to the Agency for Health Care Policy and Research (AHCPR), "the primary 
strategy for preventing colorectal cancer deaths is to detect and remove precursors 
of colorectal cancer or to detect and treat cancer in its earliest stages". 5 
The precursors of colorectal cancer mentioned above are the premalignant 
mucosal masses in the colon and rectum----otherwise known as adenomatous 
polyps. These colorectal cancer precursors are found in about 25% of the 
popUlation by age 50. While the traditional screening methods are effective in 
detecting adenomatous polyps, they are often not en1ployed. If the current 
screening methods are not being used enough, one solution is to develop new, 
easier screening methods. A suggestion of the AHCPR is to use the recent 
discoveries in the molecular biology of colorectal cancer to develop new screening 
interventions.5 
One recent discovery in the molecular biology of colorectal cancer is the increased 
expression of the cyclooxygenase-2 (COX-2) enzyme. In 85% of human 
colorectal adenocarcinomas, COX-2 levels are 2 to 50 times greater in the cancer 
tissue than in surrounding tissue.6 And, it is now thought that COX-2 is not 
simply present in colorectal cancer; the enzyme is actually needed for the 
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development of this cancer.7 As mentioned earlier, the inhibition ofCOX-2 by 
NSAIDs, like aspirin, reduces human colorectal cancer risk by 40-50%.6 With a 
specific COX-2 inhibitor, the chemopreventive effects ofNSAIDs can be obtained 
without the GI side effects. In one study, celecoxib supplementation inhibited the 
incidence and multiplicity of colon tumors in rats by 93 and 97% respectively. 8 
The chemopreventive benefits of celecoxib have led to its recent approval by the 
Food and Drug Administration as a supplement to standard treatment for familial 
adenomatous polyposis. 
In addition to celecoxib' s chemopreventive benefits, it may serve as a means to 
devise a new screening method. Not only is COX-2 found in much higher 
concentrations in colorectal cancer adenocarcinomas, the degree of expression 
may be related to the severity and stage of the disease. Greater COX-2 expression 
is found in larger tumors and in the later stages of the disease, and lymph node 
metastasis appears to increase COX-2 expression even further. Higher 
concentration of the enzyme also corresponds to decreased survival estimates.9 
Because the COX-2 enzyme is inextricably linked to colorectal cancer, it can be 
used as a marker of the disease. This is why the focus of this research, the 
synthesis of a radiolabeled celecoxib derivative, might be useful. Labeling a 
known COX-2 inhibitor with 1231 should allow single-photon emission computer 
tomography (SPECT) of colorectal cancer. The 123I-Iabeled celecoxib derivative 
would localize in the area of increased COX-2 expression caused by colorectal 
adenocarcinomas, and this localization would allow scintigraphy. 
Chemistry: The development of a synthetic route to radiolabeled methyl and 
methoxy derivatives of celecoxib was originally planned; however, only the 
iodinated methoxy derivative was synthesized due to time constraints. The first 
synthetic plan required the iodination of 4-methoxyacetophenone, but this reaction 
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failed to produce the desired product. Finally, 2-iodoanisole, 1, was chosen as the 
starting material for the synthesis. 
4-[5-(3-Iodo-4-methoxyphenyl)-3-trifluoromethylpyrazol-l-yl] 
benzenesulfonamide, 6, was synthesized from 2-iodoanisole, 1, in four steps as 
shown in the Scheme. The reaction sequence could have been limited to three 
steps if the remethylation of 4-hydroxy-3-iodoacetophenone, 2, had not been 
necessary. After the Friedel-Crafts acylation, the reaction mixture was allowed to 
stand at room temperature, which led to demethylation by the Lewis acid, 
aluminum chloride. The first step was the Friedel-Crafts acylation of the 
iodoanisole 1 to form 3-Iodo-4-methoxyacetophenone, 3, and this was followed by 
a Claisen condensation with methyl trifluoroacetate. The 4,4,4-trifluoro-l-(3-
iodo-4-methoxyphenyl)butane-l,3-dione, 4, formed was then reacted with the 
sulfonamide 5 in ethanol to give the iodinated methoxy celecoxib derivative 6. 
The final two steps in the Scheme were developed for use in the radioiodination 
sequence (which was not carried out due to time constraints). 
The key step in the synthesis is the electrophilic iododestannylation of 4-[5-(4-
methoxy-3-trimethylstannanylphenyl)-3-trifluoromethylpyrazol-l-yl] 
benzenesulfonamide, 7. Palladium catalyzed deiodostannylation with 
hexamethylditin in dioxane gave the tin precursor 7. The tin compound 7 was 
then converted back to the iodinated celecoxib derivative 6 by heating with NaI 
and 0.3% peracetic acid. These are the conditions utilized for radioiodine 









































Experimental Section: All the reactions were performed using dry solvents in a 
nitrogen atmosphere. The starting materials were purchased from Aldrich 
Chemical Company. The products were purified by flash chromatography (Si02), 
and the IH spectra were taken with a Bruker AC 250 MHz NMR spectrometer. 
The chemical shifts are given in parts per million relative to tetramethylsilane. 
The melting points were recorded on an Electrothermal Digital Melting Point 
Apparatus and are uncorrected. 
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4-Hydroxy-3-iodoacetophenone (2) 
2-Iodoanisole, 1, (11.7 g, 0.050 mol) was dissolved in dry carbon disulfide (30 
mL) and transferred to a 100 mL three-necked flask, equipped with a reflux 
condenser, a sealed stirrer unit, and a dropping funnel protected with a Drierite 
guard tube. Powdered anhydrous aluminum chloride (15 g, 0.11 mol) was added 
and the mixture was heated to gentle refluxing. Acetic anhydride (5.1 g, 0.50 mol) 
was added through the dropping funnel. Refluxing was continued for 2 hours, and 
the reaction mixture was left at room temperature overnight. The reaction mixture 
poured into a mixture of crushed ice (100 g) and concentrated hydrochloric acid 
(30 mL). After extraction with ether (2x100 mL), the combined organic extracts 
were washed with water and then 10% sodium hydroxide (50 mL). The sodium 
hydroxide extract was neutralized with 10% hydrochloric acid (50 mL). The 
aqueous portion was extracted with ether (2x 100 mL) and the combined ethereal 
extracts were washed sequentially with water and brine. The solution was dried 
over anhydrous sodium sulfate and the solvent removed under reduced pressure to 
give a pinkish solid. The crude yield was 9.80 g (74.8 %). IH NMR (CDC13): 8, 
2.55 (s, 3H), 7.00 (d, 1H), 7.90 (d, 1H), and 8.30 (s, 1H). 
3-Iodo-4-methoxyacetophenone (3) 
4-Hydroxy-3-iodoacetophenone, 2, (2.70 g, 10.3 mmol) was transferred to a 
double necked flask equipped with a reflux condenser and a septum protected with 
a Drierite guard tube. The solid w~s dissolved in dry DMF (80 nlL). An excess of 
CH31 (2.20 g, 15.5 mmol) and K2C03 (2.17 g, 15.5 mmol) was added to the 
solution. The reaction mixture was stirred while heating at 60°C for 24 hours. 
The mixture was then cooled to room temperature and the solvent removed under 
reduced pressure. The solid was purified by column chromatography with 3: 1 
petroleum ether/ethyl acetate as the mobile phase to obtain a light yellow product. 
The yield of pure product was 2.51 g (88%). IH NMR (CDCh): 8,2.55 (s, 3H), 
3.95 (s, 3H), 6.85 (d, 1H), 7.95 (d, 1H), and 8.35 (s, 1H). 
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4,4,4-Trifluoro-l-(3-iodo-4-methoxyphenyl)butane-l,3-dione (4) 1 0 
3-Iodo-4-methoxyacetophenone, 3, (1.17 g, 4.24 mmol) was transferred to a 
double necked flask equipped with a reflux condenser and a septum protected with 
a Drierite guard tube. The solid was dissolved in dry methanol (2.7 mL) and 
sodium methoxide (1.3 mL, 25% solution in methanol) was added. The mixture 
was stirred for 5 minutes. Methyl trifluoroacetate (0.60 mL, 5.0 mmol) was then 
added. After refluxing for 24 hours, the reaction mixture was cooled to room 
temperature. The solvent was removed under reduced pressure and the reaction 
was quenched with HCI (3N, 11 mL). The product was extracted with ethyl 
acetate (4x7.5 mL), and the extracts dried over anhydrous MgS04 and filtered. 
The solvent was removed under reduced pressure, and the brown oil was purified 
by column chromatography using a 3: 1 petroleum ether/ethyl acetate mobile 
phase. This gave 0.74 g (66%) of a light pink solid. IH NMR (CDCh): 0,4.00 (s, 
3H), 6.50 (s, IH), 6.90 (d, IH), 7.95 (d, IH), and 8.40 (s, IH). 
4-[ 5-(3-Iodo-4-methoxyphenyl)-3-trifluoromethylpyrazol-l-yI] 
benzenesulfonamide (6) 10 
Dione 4 (1.27 g, 3.41 mmol) was transferred to a double necked flask equipped 
with a reflux condenser and a septum protected with a Drierite guard tube. 
The compound was dissolved in dry ethanol (50 mL) and 4-
sulfonamidophenylhydrazine hydrochloride, 5, (0.90 g, 4.0 mmol) was added to 
the solution. The reaction mixture was then refluxed and stirred for 20 hours. The 
solution was cooled to room temperature and solvent was removed under reduced 
pressure. The product was purified by a flash chromatography column (Si02) 
using petroleunl ether/ethyl acetate (2: 1) as the mobile phase; a yellow solid was 
obtained. The iodinated methoxy celecoxib derivative 6 weighed 1.16 g (65%): 
melting point 183-185 °C. IH NMR (CDCh): 0,3.69 (s, 3H), 4.89 (s, 2H), 6.73 (s, 
IH), 6.74 (d, IH, J = 8.5 Hz), 7.02 (s, IH, J = 8.5 Hz), 7.47 (d, 2H, J = 8.5 Hz), 




The iodinated methoxy celecoxib derivative 6 (0.55 g, 1.1 mmol) was placed in a 
double necked flask equipped with a reflux condenser and flushed with nitrogen. 
Anhydrous 1,4-dioxane (12 mL), hexamethylditin (0.540 g, 1.65 mmol), and 
tetrakis(triphenylphosphine)palladium (--0.05 g) were added sequentially. The 
reaction nlixture was stirred at reflux for 2.5 hours. The solution was cooled to 
room temperature and filtered. The solvent was removed under reduced pressure, 
and the tin compound 7 was purified by column chromatography with 2: 1 
petroleum ether/ethyl acetate as the mobile phase. A yellowish gel was obtained 
in a yield of 0.50 g (81 %). IH NMR (CDCh): 0, 0.27 (s with Sn satellites, J Sn-CH 
= 54 Hz, 9H), 3.61 (s, 3H), 4.91 (s, 2H), 6.73 (s, IH), 6.75 (d, IH, J = 8.5 Hz), 
7.14 (d, IH, J = 8.5 Hz), 7.24 (d, IH), 7.50 (d, 2H, 8.5 Hz) and 7.94 (d, 2H, J = 8.5 
Hz). 
4-[ 5-(3-Iodo-4-methoxy-phenyl)-3-trifluoromethyl-pyrazol-l-yl]-
benzensulfonamide (6) from Stannane precursor 
To a solution of tin precursor 7 (11. 4 mg, 0.02 mmol) in methanol (0. 3 mL) was 
added a solution of sodium iodide (6.0 mg, 0.04 mmol) in water (0. 1 mL). 
Peracetic acid (1.0 mL, 0.3 % methanolic solution, 0.04 mmol) was slowly added 
and the reaction mixture stirred for 10 min. Excess iodine was decomposed by a 
drop of 10% sodium thiosulfate solution. The progression of the reaction was 
followed on TLC by comparing with an authentic sample. A major portion of the 
starting tin precursor was transformed to the iodo compound 6. 
Conclusions: The iodinated methoxy celecoxib derivative 6 was synthesized and 
regenerated after stannylation via an oxidative iodination suitable for the 
preparation of radioiodinated celecoxib derivative 6. The fact that the iodinated 
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compound was easily regenerated indicates that the radiolabeling will be 
successful. Radiolabeling experiments are currently in progress. 
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